PAVmed (PAVM) Expected to Release Earnings on Friday

PAVmed (NASDAQ:PAVM) is expected to announce its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to post earnings of ($0.63) per share and revenue of $0.0480 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 8:30 AM ET.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.48). PAVmed had a negative return on equity of 146.19% and a negative net margin of 21,914.12%.The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.07 million. On average, analysts expect PAVmed to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

PAVmed Trading Down 0.8%

Shares of PAVM stock opened at $4.71 on Wednesday. PAVmed has a 1 year low of $3.85 and a 1 year high of $28.44. The firm has a market capitalization of $4.69 million, a PE ratio of -0.13 and a beta of 0.54. The stock has a fifty day moving average of $5.22 and a two-hundred day moving average of $7.66. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.02.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its position in PAVmed stock. Geode Capital Management LLC raised its holdings in PAVmed Inc. (NASDAQ:PAVM) by 74.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 168,832 shares of the company’s stock after acquiring an additional 72,258 shares during the quarter. Geode Capital Management LLC owned 17.23% of PAVmed worth $40,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 19.93% of the company’s stock.

Analysts Set New Price Targets

PAVM has been the topic of a number of recent analyst reports. Ascendiant Capital Markets cut their price objective on shares of PAVmed from $65.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, PAVmed currently has a consensus rating of “Hold” and an average target price of $56.00.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.